Sherpa Clinical Packaging announces completion of move to a new GMP clinical Packaging and Distribution facility in San Diego
Sherpa, a clinical packaging company strategically located in the heart of the San Diegobiotech community, demonstrates commitment to its clinical trial materials management business by investing in infrastructure. The new state-of-the-art facility is 37,500 ft2 and offers enhanced capabilities and a strict cold chain management infrastructure. The expansion was needed to support the company’s increased demand for Phase 2 and Phase 3 clinical studies and is a result of continued growth serving new and existing clients.
The new facility offers purpose built space for primary and secondary clinical labeling and packaging, GMP storage for refrigerated (2-8oC), frozen (-20oC, -80oC and LN2), and controlled room temperature (20-25oC), and temperature controlled shipping dispatch. The facility also comprises an ISO 8 clean room for primary packaging of solid dose products. Sherpa now also specializes in cold form and thermoform blistering, blister strip carding, pouching and API storage.
Sherpa was able to successfully move its operations to the new facility without service interruptions. “When they moved to their new facility, we were in the middle of a clinical trial,” David R., of OrthoTrophix reflected, “The transition was seamless and they did not miss a beat. As a small, virtual company, we rely heavily on our contractors to be an extension of our team. Sherpa filled that role beautifully for us as they managed the distribution of our drug to clinical sites.”
“The new Sherpa facility will help sustain the continued growth of our company,” said Mark Paiz, president of Sherpa Clinical Packaging. “We are excited to be able to provide the diversity and quality of services to a large number of clients in all phases of clinical trials. Sherpa’s mission is to be the customer service leader in the clinical trial materials management business and we offer each client the trusting and reliable relationship that people vested in clinical trials seek.”